Identification of causal intervention effects under contagion by Cai, Xiaoxuan et al.
Identification of causal intervention effects under contagion
Xiaoxuan Cai1, Wen Wei Loh2, and Forrest W. Crawford1,3,4,5
1. Department of Biostatistics, Yale School of Public Health
2. Department of Data Analysis, University of Ghent
3. Department of Statistics & Data Science, Yale University
4. Department of Ecology and Evolutionary Biology, Yale University
5. Yale School of Management
December 11, 2019
Abstract
Defining and identifying causal intervention effects for transmissible infectious disease outcomes
is challenging because a treatment – such as a vaccine – given to one individual may affect the
infection outcomes of others. Epidemiologists have proposed causal estimands to quantify effects
of interventions under contagion using a two-person partnership model. These simple concep-
tual models have helped researchers develop causal estimands relevant to clinical evaluation of
vaccine effects. However, many of these partnership models are formulated under structural
assumptions that preclude realistic infectious disease transmission dynamics, limiting their con-
ceptual usefulness in defining and identifying causal treatment effects in empirical intervention
trials. In this paper, we propose causal intervention effects in two-person partnerships under
arbitrary infectious disease transmission dynamics, and give nonparametric identification results
showing how effects can be estimated in empirical trials using time-to-infection or binary out-
come data. The key insight is that contagion is a causal phenomenon that induces conditional
independencies on infection outcomes that can be exploited for the identification of clinically
meaningful causal estimands. These new estimands are compared to existing quantities, and
results are illustrated using a realistic simulation of an HIV vaccine trial.
Keywords: infectiousness, interference, mediation, susceptibility, transmission, vaccine
1 Introduction
Estimating the causal effect of an intervention can be challenging when the outcome of interest is
contagious [34]. For example, a vaccine intended to prevent infection by a transmissible disease
may reduce the risk of infection in individuals who receive it, and may reduce transmissibility
if a vaccinated individual becomes infected. When study subjects are embedded in interacting
groups among whom the disease may be transmitted, it can be difficult to separate the effect of one
subject’s vaccination on themselves from its effect on other individuals and the group as a whole.
Usually, the estimand of greatest clinical interest is the effect of an intervention on individual risks
of infection, holding all else constant.
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The pursuit of empirically meaningful definitions of population-level causal vaccine effects has a
long history. Greenwood and Yule [16] first described informally the conditions under which vaccine
effects can be estimated. Halloran et al. [21] established some of the first theory and definitions for
clinically meaningful vaccine effects, and subsequent work by Halloran and colleagues [19, 23, 24]
described epidemiological study designs for identifying these quantities. Halloran and Struchiner
[20] gave the first formal definitions of causal vaccine estimands using notation and assumptions
of a modern counterfactual-based causal inference framework [48]. Hudgens and Halloran [26] and
Perez-Heydrich et al. [42] showed how this formalism could be applied in empirical randomized
trials of clustered individuals [18, 25]. More recently, researchers have shown that randomized
trials may not measure clinically meaningful intervention effects when infection can be transmitted
within groups [13, 33].
Researchers have described two-person partnership models of infectious disease transmission for
defining more granular, or individual, causal intervention effects. VanderWeele and Tchetgen [55]
introduced a partnership model consisting of two interacting individuals who may be vaccinated and
can transmit the infection to each other. By limiting the extent of potential disease transmission
to two individuals, effects can be more easily defined in terms of potential outcomes indexed by
treatments of both individuals and the outcome of their partner. Using a principal stratification
approach, the partnership model permits computations of bounds for the infectiousness effect [9,
17, 55].
VanderWeele et al. [56] presented a special case of the partnership model in which one partner
is home-bound, and can only be infected from within via infection of the other. The assumed
asymmetry in the disease transmission structure makes this model tractable for point identification
of contagion and infectiousness effects by ensuring that interference only happens in one direction.
Interference arises when an individual’s potential outcomes depend on the treatment status of others
[12]. To allow for mutual dependence of potential outcomes on each other’s treatments, Ogburn
et al. [35, 36] extend this approach using causal diagrams and mediation arguments for symmetric
pairs. More recent work on symmetric mediation provides new tools for accommodating structural
assumptions about the nature of dependence in outcomes under different forms of interference
[5, 37, 49, 50].
Statisticians and epidemiologists have developed parallel literature devoted to mathematical mod-
eling of infectious disease transmission dynamics. This work treats infectious disease transmission
as a dynamic temporal phenomenon: the risk of infection in a given subject may change over
time, as a function of the infection status of their contacts, and covariates. For example, Rhodes
et al. [44] present hazard models of infectious disease transmission in groups that accommodate
individual-level (e.g. treatment) variables with possibly different effects on susceptibility and in-
fectiousness. Kenah [28, 29] extends these ideas to develop nonparametric and semi-parametric
statistical models for estimating covariate effects under contagion. Structural transmission mod-
eling has gained wide use in clinical studies of infectious disease dynamics because it combines
mechanistic assumptions about infectious disease transmission with regression-style covariate ad-
justment [2–4, 6–8, 39, 52, 53, 57].
In this paper, we take a different approach to defining and identifying causal identification for in-
tervention effects in general symmetric two-person partnerships under contagion by formalizing the
role of time in infectious disease transmission from a causal perspective. In our construction, either
individual can be vaccinated, can be infected from outside, and can infect the other if infected
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themselves. Treatments and individual covariates may affect both susceptibility to, and infectious-
ness of, the infection outcome. We first introduce a generic causal model and straightforward
assumptions that permit identification of time-controlled and marginal contagion, susceptibility,
and infectiousness effects. The framework is nonparametric and imposes no restrictions on the
joint distribution of infection times in a partnership. Our method generalizes those that treat
infection outcomes as simultaneous mediating variables [9, 17, 55]. Before any infections have oc-
curred in a partnership, the potential first infection times are conditionally independent, because
neither partner can yet transmit the infection to the other. After the first infection, the causal
structure of the system changes, and the time to infection of the remaining susceptible partner is
now a function their partner’s, as well as their own, treatment and covariates. Because the result-
ing causal model incorporates this temporally changing structure, it is more complex than those
presented by other authors. On the other hand, this added complexity yields straightforward point
identification results that cannot be obtained by treating the infection outcomes of both individuals
as simultaneous mediating variables. We discuss nonparametric identification under randomization
and in observational settings, compare these estimands to existing quantities proposed by other
authors, and conduct a simulation analysis of a hypothetical HIV vaccine trial to illustrate the
estimands.
2 Setting
Consider a population consisting of pairs of individuals, henceforth referred to as partnerships.
Within a partnership, either individual can be infected from an external source (exogenous to
the partnership), and once infected, an individual may internally (endogenous to the partnership)
transmit the infection to their uninfected partner. In line with existing partnership models, it is
assumed throughout that transmission between partnerships does not occur. Label the individuals
in the partnership 1 and 2. In a given partnership, let Ti be the infection time of person i, and
let Yi(t) = 1{Ti < t} be the indicator of prior infection at time t. Let Xi be the binary treatment
status of i, and let X = (X1, X2) be the joint binary treatment vector for the partnership. Let
L = (L1,L2) be measured baseline covariates for the two individuals, including covariates for the
partnership as a whole. In each partnership, we observe (T1, T2, X1, X2,L1,L2). In a symmetric
partnership, labels 1 and 2 are arbitrary and interchangeable. We will use the index i to refer
generically to one individual, either 1 or 2, and j to refer to the partner of i.
To describe the causal structure of infectious disease transmission within a partnership, we consider
a decomposition of the infection time Ti that will help us define counterfactual infection times under
different circumstances. Recall that both individuals are uninfected at baseline, and let Wi be the
time to initial infection of i from a source of infection external to the partnership. If i is the first
in their partnership to become infected, then we observe Wi. If their partner j is infected first, we
observe Wj = wj and Wi is censored at time wj . When Wi is censored by earlier infection of j, let
Zi be the additional time to infection of i, beyond wj . Formally, we decompose Ti as follows.
Ti =
{
Wi if Wi < Wj
Wj + Zi otherwise.
(1)
We emphasize that the decomposition (1) is purely notational, and places no a priori restrictions
on the joint distribution of infection times (Ti, Tj). Rather, (1) permits specification of causal
assumptions, outlined below, to capture the way treatments to both i and j may affect different
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Figure 1: Illustration of contagion in a two-person partnership. At left, when subject 2 becomes
infected first (W2 < W1), then W1 is censored, and Z1 is the remaining time to infection of subject
1. At right, when subject 1 is infected first (W1 < W2), then W2 is censored, and Z2 is the
remaining time to infection of subject 2. Informally, the outcome is said to be “contagious” when
the distribution of Ti is different from that of Wi.
parts of the waiting times to infection. Figure 1 illustrates this decomposition and motivates the
contagion effect presented in Definition 1 below: the disease is said to be “contagious” if the
distribution of Ti is different from that of Wi, or equivalently, if prior infection of j changes the
conditional distribution of the remaining time to infection of i.
2.1 Assumptions
In this section, we describe assumptions that are sufficient to identify scientifically meaningful
and relevant causal effects, which are described later, from observable infection time data for each
partnership. We state assumptions for a generic individual i and their partner j. To define potential,
or counterfactual, infection times for individual i, let Wi(x) be the potential value of Wi under the
joint treatment allocation x = (x1, x2). Let Zi(wj ,x) be the additional potential time to infection
of i, following the infection of j at time Wj(x) = wj , under joint treatment allocation x.
Assumption 1 (Exclusion restriction and independence of the initial infection). Wi(x) = Wi(xi),
Wi(xi) |= Wj(xj) | L, and Wi(xi) |= Lj | Li, for all x.
Assumption 1 states that individual i’s initial infection time Wi(x) is invariant to the partner’s
treatment status xj , and may be viewed as a “no-interference” assumption on Wi, since Wi is the
initial infection time from an external source, which can only be realized when Wi precedes Wj .
Further, Wi(xi) is independent of Wj(xj) given covariates L.
Assumption 2 (Initial infection exchangeability). Zi(wj ,x) |= Wj(xj) | L, for all x, wj > 0.
Assumption 2 states that there is sufficient covariate information in L so that the potential further
time to infection Zi(wj ,x) when j is infected at wj is conditionally independent of the potential
initial infection timeWj(xj) of j. While this assumption bears similarity to the assumption of no un-
observed confounding between the mediator and outcome counterfactuals (for the same individual)
under the single mediator setting [41, 47], we note that this assumption relates to counterfactuals
for different individuals.
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Assumption 3 (Treatment exchangeability). Wi(xi) |= X | L and Zi(wj ,x) |= X | L, for all x,
wj > 0.
Assumption 3 means that the potential infection times Wi(xi) and Zi(wj ,x) are independent of
the assigned treatment X given covariates. This assumption resembles the conventional criterion
of “no unobserved confounding” between treatment and outcome; in this context, Assumption 3
states that there is no unmeasured confounding between two infection times and the joint treatment
vector in the same partnership.
Two additional assumptions ensure identifiability of potential infection outcomes from observational
data.
Assumption 4 (Consistency). Wi = Wi(xi), and Zi = Zi(wj ,x) under the observed treatment
X = x and infection time Wj = wj, for all x, wj > 0.
Assumption 5 (Positivity). 0 < Pr(Wj < w|Xi = xi,Li = li) < 1 for all w > 0, xi, and li;
0 < Pr(Zj < z|X = xi,L = l) < 1 for all z > 0, x and l; and 0 < Pr(X = x|L = l) < 1 for all l.
A final assumption permits identification of certain “natural” or “cross-world” potential infection
outcomes.
Assumption 6 (Cross-world initial infection exchangeability). Zi(wj ,x) |= Wj(x′j) | L when x =
(xi, xj) and x
′
j 6= xj, for all x, x′j.
Finally, let Ti(Wj(xj),x) be the potential outcome for the infection time of subject i, when j is
infected at time Wj(xj) and the assigned treatments are x = (xi, xj). Following the decomposition
(1) and by Assumptions 1–3, we can construct the potential infection time Ti(Wj(xj),x) as follows:
Ti(Wj(xj),x) =
{
Wi(xi) if Wi(xi) < Wj(xj)
Wj(xj) + Zi(Wj(xj),x) otherwise.
(2)
The potential infection time with Wj = wj fixed is denoted as Ti(wj ,x). For convenience, define
the binary potential infection outcome evaluated at time t, Yi(t;wj ,x) = 1{Ti(wj ,x) < t} and
Yi(t;Wj(x
′
j),x) = 1{Ti(Wj(x′j),x) < t}.
The potential infection time decomposition (2) formalizes intuition about the structure of inter-
ference under contagion: there can be no interference without prior infection. When neither i nor
j is infected, the time to infection of i is solely a function of the treatment xi, and there is no
interference within the partnership. This is because the treatment xj of j can only affect i after j
becomes infected. When j is the first to be infected, the remaining time to infection of i is now a
function of both xi and xj , because j has now gained the ability to transmit to i. This apparent
complexity simplifies identification of causal effects, as we show below.s
3 Identification of potential infection outcomes
We wish to non-parametrically identify the average potential infection outcome E[Yi(t;wj ,x)] using
observations of pairwise outcomes, treatments, and covariates (Ti, Tj , Xi, Xj ,Li,Lj). A preliminary
result identifies the distribution of Wi(xi) in Lemma 1 using information about infection times.
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Lemma 1. Suppose Assumptions 1-5 hold. Then the distribution function of Wi(xi) given Li = li
is identified by
Fi(w|xi, li) = 1− exp
[
−
∫ w
0
p(Ti = u, Tj > u|X = (xi, xj),L = (li, lj))
Pr(Ti > u, Tj > u|X = (xi, xj),L = (li, lj))du
]
for any fixed values of xj, and lj, where p(Ti = u, Tj > u|X = (xi, xj),L = (li, lj)) is the joint
probability density of Ti and survivor function of Tj.
Lemma 1 is a standard distributional identification result in competing risks [1]; in this paper,
Wi and Wj are competing event times within the same partnership. The identified distribution
function Fi(w|xi, li) is a function of xi and li only, and is invariant to values of xj and lj . However,
in order to identify this function, particular values of xj and lj must be held constant.
The main result shows that average exposure-controlled potential infection outcomes given L = l
are identified. Proofs are given in the Appendix.
Theorem 1 (Identification of the average exposure-controlled potential infection outcome). Sup-
pose Assumptions 1-5 hold and x = (x1, x2). For fixed values of wj and t, if wj < t,
E[Yi(t;wj ,x)|L = l] = Fi(wj |xi, li) + (1− Fi(wj |xi, li))E[Yi(t)|Ti ≥ wj , Tj = wj ,X = x,L = l] (3)
otherwise, if t ≤ wj, E[Yi(t;wj ,x,L = l)] = Fi(t|xi, li).
The structure of (3) shows that the average controlled potential infection outcome Yi(t;wj ,x) given
L = l is equal to the probability that i is infected before wj , plus the average outcome of i when j is
infected at wj and i is not yet infected, times the probability of this event. Figure 2 shows a causal
graphical model [40] of the system outlined by Assumptions 1-5, and the corresponding single-world
intervention graph [45, 46] for identification of the exposure-controlled potential infection outcome.
If we do not fix the infection time Wj = wj , and instead allow it to take its “natural” value under a
particular treatment to j, we obtain the marginal average potential infection outcome when L = l
as follows.
Corollary 1 (Identification of average natural potential infection outcome). Suppose Assumptions
1-5 hold. Then for x = (xi, xj), E[Yi(t;Wj(xj),x)|L = l] = E[Yi(t)|X = x,L = l]. If in addition
x′j 6= xj and Assumption 6 holds,
E[Yi(t;Wj(x′j),x)|L = l] =
∫ t
0
E[Yi(t;wj ,x)|L = l]dFj(wj |x′j , lj).
where Fj(wj |xj , lj) is given by Lemma 1 and E[Yi(t;wj ,x)|L = l] by Theorem 1.
Finally, by standardization of the potential infection outcome across the distribution of covariates
L, we can identify the average potential infection outcome. Let G(l) be the distribution function
of the joint covariate vector L = l in the population of partnerships. Then
E[Yi(t;wj ,x)] =
∫
E[Yi(t;wj ,x)|L = l]dG(l)
and
E[Yi(t;Wj(x′j),x)] =
∫
E[Yi(t;Wj(x′j),x)|L = l]dG(l)
where E[Yi(t;wj ,x)|L = l] and E[Yi(t;Wj(x′j),x)|L = l] are given by Theorem 1 and Corollary 1
respectively.
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Figure 2: Causal graphical model for infection outcomes in a two-person partnership, under As-
sumptions 1–5. At left, covariates L1 and L2 may be dependent within partnerships, and covariates
of both subjects may affect the joint treatments (X1, X2). The initial infection times W1 and W2
are functions of individual covariates and treatments alone by Assumption 1, and thus no arrows
exist from Xj to Wi or from Lj to Wi. Subsequent infection times Z1 and Z2 are functions of treat-
ments and covariates of both subjects, and the infection time of the first infected subject. From
the decomposition of the infection time (1), the infection time Zi is not a function of the (possibly
latent) time Wi. The overall infection time Ti is determined by Wi, Wj and Zi, as specified in
(1). At right, the single-world intervention graph illustrates identification of Y1(t;w2,x) under the
intervention in which Wj = wj and X = (x1, x2) are fixed. The variables Z2 and T2 are omitted
since they are not relevant to generation of the outcome T1(w1,x).
4 Causal estimands
Contrasts of potential infection outcomes under different treatments x and infection times wj can
yield epidemiologically meaningful causal estimands. In this paper, we express causal contrasts as
differences of average potential infection outcomes. Effect measures on the hazard ratio, risk ratio,
or odds ratio scales may be defined similarly [e.g. 21, 38].
First, the contagion effect captures the change in infection risk in one individual due to a change
in the infection time of their partner.
Definition 1 (Contagion effect). For wj 6= w′j and treatment x = (xi, xj), the controlled contagion
effect is CE(t, wj , w
′
j ,x) = E[Yi(t;wj ,x)−Yi(t;w′j ,x)] and the natural contagion effect is CE(t,x) =
E[Yi(t;Wj(0),x)− Yi(t;Wj(1),x)].
We say that the infection outcome (absent treatment) is “positively contagious” if for all infection
times wj < w
′
j with wj < t, the controlled contagion effect under no treatment is CE(t, wj , w
′
j ,0) >
0. In this way, we interpret contagion, or outcome transmissibility, as a causal phenomenon that
need not depend on treatments: under positive contagion, earlier infection of one’s partner causes
one to become infected earlier, on average. On the other hand, the natural contagion effect CE(t,x)
captures features of the treatment effect: it replaces fixed values of wj and w
′
j with their counterfac-
tual values under no treatment versus treatment of j, similar to the effect proposed by VanderWeele
et al. [56] for an asymmetric partnership. The natural contagion effect is a “cross-world” estimand
because it integrates the average potential infection outcome E[Yi(t;wj ,x)] with respect to the
distribution of Wj(x
′
j) under a treatment Xj = x
′
j that cannot arise in the same realization as
Xj = xj . Figure 1 can be reinterpreted in light of Definition 1: positive contagion means that
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earlier infection of j causes i to become infected earlier, compared to the infection time of i that
would have occurred, had Wj happened later.
The susceptibility effect is of interest in vaccine trials because it summarizes the clinical effect of an
intervention on the individual who receives it, holding the treatment status and infection time of
their partner constant [15, 20, 23]. The susceptibility effect is sometimes called the “per-exposure
effect” because it holds the distribution of exposure to infectiousness constant [38].
Definition 2 (Susceptibility effect). For wj > 0 and Xj = xj, the controlled susceptibility of effect
is SE(t, wj , xj) = E[Yi(t;wj , xi = 1, xj)−Yi(t;wj , xi = 0, xj)] and the natural susceptibility effect is
SE(t, xj) = E[Yi(t;Wj(xj), xi = 1, xj)− Yi(t;Wj(xj), xi = 0, xj)].
If the controlled susceptibility effect is negative for every wj and xj , this means that the treatment
is beneficial to the individual who receives it. Note that the natural susceptibility effect is not a
cross-world estimand: it averages potential infection outcomes with respect to the distribution of
Wj(xj), where xj is the treatment under which the infection outcome of i is realized.
The infectiousness effect summarizes the effect of changing the treatment to j on the infection risk
of i, while holding the treatment to i and the infection time of j unchanged.
Definition 3 (Infectiousness effect). For wj > 0 and Xi = xi, the controlled infectiousness effect
is IE(t, wj , xi) = E[Yi(t;wj , xi, xj = 1) − Yi(t;wj , xi, xj = 0)] and the natural infectiousness effect
is IE(t, xi) = E[Yi(t;Wj(0), xi, xj = 1)− Yi(t;Wj(0), xi, xj = 0)].
The natural infectiousness effect is a cross-world estimand because the first term in the contrast
specifies that the infection time of j is realized under xj = 0, but the infectiousness of j subse-
quently is realized under xj = 1. Several authors have described the natural infectiousness effect
as unidentified even under randomization when only binary infection outcomes are recorded at
follow-up [9, 9–11, 17, 55, 56]. Corollary 1 and Definition 3 together show why this is the case. The
correct marginalization over infection times Wj(x
′
j) cannot be computed unless the distribution of
Wj(xj) is identified as in Lemma 1. The controlled and natural infectiousness effects are similar to
those proposed by Chiba and Taguri [11], but here the marginalization is over the infection time of
j, not their binary infection outcome.
5 Comparison to other infectious disease intervention effects
Statisticians and epidemiologists have proposed a wide variety of estimands summarizing the effect
of interventions for contagious outcomes, often in the two-person partnership setting. In this
section, we evaluate the meaning of alternative definitions of vaccine effect estimands in the context
of the causal effects defined above. We take the contagion, susceptibility, and infectiousness effects
defined above as fundamental characteristics of the disease transmission process and intervention
under study. Whenever possible, we characterize the sign, or direction, of alternative effects, as
a function of these primitives. In some cases, where the relationship is complex, we evaluate the
alternative estimands under a null hypothesis, for example when the controlled susceptibility or
infectiousness effect is zero, so that explicit results can be analytically proven. For simplicity, we
omit the role of covariates L in the comparison of estimands.
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The “attack rate” of an infectious disease is defined for individuals with treatment x as ARx(t) =
E[Yi(t)|Xi = x]. The ratio of attack rates, sometimes called “relative cumulative incidence”, has
been used to measure the vaccine effect on susceptibility, defined as VEAR(t) = 1−AR1(t)/AR0(t)
[14, 16]. A related estimand, called the “direct effect”, is a contrast on the difference scale, DE(t) =
AR1(t)− AR0(t) when treatment is randomized within groups [26]. In the symmetric partnership
setting, attack rates ARx(t) that condition only on the treatment to i implicitly marginalize over
treatment to j.
Theorem 2. Suppose SE(t, wj , xj) = 0 and IE(t, wj , xj) < 0 for all xj and wj > 0. If X = (Xi, Xj)
is positively dependent, then DE(t) < 0 and VEAR(t) > 0; if X is negatively dependent then
DE(t) > 0 and VEAR(t) < 0; and if Xi |= Xj then DE(t) = VEAR(t) = 0. If there is no treatment
effect whatsoever, SE(t, wj , x) = IE(t, wj , x) = 0 for all x and wj > 0, then DE(t) = VEAR(t) = 0
for any joint distribution of X.
In other words, VEAR(t) and DE(t) may or may not recover the sign, or direction, of the suscep-
tibility effect, depending on the susceptibility and infectiousness effects, and the joint distribution
of X within clusters. Morozova et al. [33] and Eck et al. [13] proved similar results in a parametric
setting under Bernoulli, block, and cluster randomization for the joint treatment X in clusters or
partnerships. Halloran et al. [21], Halloran et al. [22], Halloran et al. [23] and Rhodes et al. [44]
warned that VEAR(t) may be a biased approximation to the susceptibility effect due to differential
exposure to infection between treated and untreated individuals in clusters.
Related definitions of the attack rate condition on the treatments to both individuals in the part-
nership. The attack rate among individuals with treatment x whose partner has treatment x′ is
ARx,x′(t) = E[Yi(t)|Xi = x,Xj = x′]. The indirect effect is defined as IDE(t) = AR01(t)−AR00(t)
[26], and is equivalent to the difference of the natural infectiousness and contagion effects defined
above:
IDE(t) = E[Yi(t;Wj(1), (0, 1))− Yi(t;Wj(0),0)]
= E[Yi(t;Wj(1), (0, 1))− Yi(t;Wj(0), (0, 1))] + E[Yi(t;Wj(0), (0, 1))− Yi(t;Wj(0),0)]
= −CE(t, (0, 1)) + IE(t, 0).
The secondary attack rate is defined as SARx′,x(t) = E[Yi(t)|Tj < t, Ti > Tj , Xi = x,Xj = x′],
the average infection status of i when j is infected during the study before i, under treatments
x and x′ to i and j respectively. The “secondary attack rate for infectiousness” is defined as
VEnetI (t) = 1 − SAR10(t)/ SAR00(t) [17]. We analyze VEnetI (t) under the null hypothesis of no
infectiousness effect, and show that when the infection is contagious and there is a susceptibility
effect, VEnetI (t) may nevertheless be nonzero. Let h0(u|0) be the hazard of of the potential infection
time Wi(0), and let h0(u|1) be the hazard of Wi(1).
Theorem 3. Suppose IE(t, wj , 0) = 0, CE(t, wj , w
′
j ,0) > 0 for all 0 < wj < w
′
j, and h0(u|1) =
εh0(u|0) with ε ∈ [0, 1), then VEnetI (t) > 0. Suppose IE(t, wj , 0) = SE(t, wj , xj) = 0 for all wj and
xj, then VE
net
I (t) = 0. Suppose CE(t, wj , w
′
j ,0) = 0 for all 0 < wj < w
′
j and h0(u|1) = εh0(u|0)
with ε ∈ [0, 1), then VEnetI (t) > 0.
In other words, when the true infectiousness effect is null, the infection outcome is positively
contagious, and the vaccine has a favorable susceptibility effect prior to the first infection, VEnetI (t)
is nonzero. In a more extreme case, when the true contagion effect is null, the disease is not
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transmissible; if the vaccine has a favorable susceptibility effect prior to the first infection, then
VEnetI (t) is still nonzero.
A simple explanation shows why VEnetI can behave in unexpected ways: is not solely a function of the
infectiousness effect. Instead, VEnetI (t) also incorporates features of the susceptibility effect on the
partner of i before the first infection occurs. When both the infectiousness and susceptibility effects
are null, VEnetI (t) recovers the correct null effect of infectiousness. Several authors have pointed out
that VEnetI (t) may suffer from selection bias because it conditions on post-randomization variables
– the infection status of both partners [17, 21–23, 44]. Halloran and Hudgens [17] use tools from
principal stratification to derive bounds for the infectiousness effect under this selection bias, and
propose a bound estimator CVEcI(t) for VE
net
I (t) under Bernoulli randomization. We analyze these
bounds by simulation below.
Several authors have recognized that simple comparison of outcomes in treated versus untreated
individuals may not suffice to identify meaningful causal effects for infectious disease interventions,
even under randomization. For example, VanderWeele [54], VanderWeele et al. [56], Ogburn et al.
[35], and Ogburn et al. [36] apply tools from mediation analysis to a simplified partnership model
to identify contagion and infectiousness effects similar to those we have defined above. In the
asymmetric partnership model, subject i is unvaccinated, home-bound, and can only be infected
by their (possibly vaccinated) partner j. To represent this structural assumption in the framework
outlined here, we force the infection time of the home-bound partner, in the absence of infection
in their partner, to be infinite. To this end, let hazard of Wi(0) be h
i
0(t|0) = 0, so that infection
of i from an external source can never occur. These authors define the infectiousness effect as
VEI(t) = E[Yi(t;Yj(1), (0, 1))] − E[Yi(t;Yj(1), (0, 0))], which contrasts the infection outcomes of i
when j is treated versus untreated, with j’s infection status Yj(xj) set to the value it would take if
j were treated.
Theorem 4. Suppose hi0(t|0) = 0 for all t > 0. Then VEI(t) = IE(t, 0).
In other words, under the asymmetric setting where i is unvaccinated and cannot be infected from
outside the partnership, VEI(t) is equivalent to the natural infectiousness effect in Definition 3.
A contagion effect is defined by VanderWeele et al. [56] as VEC(t) = E[Yi(t;Yj(1), (0, 0))−Yi(t;Yj(0), (0, 0))].
Note that this quantity reverses the difference in Definition 1, contrasting the infection outcome of
i when the infection status of j is set to the value it would obtain if j were treated versus untreated.
We provide sufficient conditions for CE(t, u, u′,0) and VEC(t) to behave similarly, that is, to have
opposite sign.
Theorem 5. Suppose hi0(t|0) = 0 for all t > 0 and SE(t, wj , 0) > 0. Then VEC(t) has opposite sign
as CE(t, wj , w
′
j ,0) for 0 < wj < w
′
j. Suppose h
i
0(t|0) = 0, SE(t, wj , 0) = 0 and CE(t, wj , w′j ,0) > 0,
then VEC(t) = 0.
In other words, in the asymmetric partnership setting, −VEC recovers the sign of the contagion
effect in Definition 1 when the vaccine has a favorable susceptibility effect prior to the first infection.
However, if the true susceptibility effect is null, VEC(t) = 0 regardless of the true contagion effect.
That is, VEC(t) is largely a measure of the susceptibility effect, and not of the transmissibility of
the infection outcome.
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6 Application: a hypothetical vaccine trial
We simulate observational and randomized trials of a hypothetical HIV vaccine in a large population
of sexual partnerships [22]. We assume individuals are not infected at baseline, but that either
individual may become infected from outside the partnership, and transmission within partnerships
may occur. To parameterize the infection transmission process, we specify hazard models for the
infection times Wi(xi) and Zi(wj ,x). This approach has been employed in extensive prior work on
statistical models for time-to-infection data [22, 27–30, 44]. For a time t > 0, Let the hazard of
Wi(xi) given covariates Li = li be given by
λWi (t;xi, li) = α(t)e
β0xi+θ
′
0li . (4)
In words, the hazard of infection in an individual whose partner is not infected, is given by a Cox
model with baseline hazard α(t). Following infection of j at time Wj = wj , the remaining potential
infection time Zi(wj ,x) given L = l = (li, lj) has hazard
λZi (t;wj ,x, l) = λ
W
i (t;xi) + γ(t− wj)eβ1xi+σxj+θ
′
1lj+θ
′
2li (5)
for t > wj . The coefficients β0 and β1 represent the change in infection risk due to vaccination of i,
and σ represents the change in transmission risk due to vaccination in j when j is infected. Covariate
effects are represented by θ0, θ1, and θ2, and α(t) and γ(t−wj) are baseline transmission hazards for
the external and internal forces of infection respectively. This specification implies that the external
force of infection and transmissibility are competing risks for infection of i [31, 32, 43]. That is,
a susceptible individual can be infected by a source of infectiousness outside their partnership, or
from an infected partner. When the baseline hazards α(t) and γ(t − wj) are time-invariant, the
model reduces to a Markov susceptible-infective process with an external force of infection [e.g
13, 33]. We consider both time-invariant baseline infection hazards α(t) = α and γ(t) = γ, and the
seasonally varying α(t) = a(1 + sin(2pit+φ)) with decaying infectiousness from an infected partner
γ(t− wj) = b exp[−ω(t− wj)]. For any functional forms of the time-varying baseline hazards α(t)
and γ(t − wj), the hazard models (4) and (5) imply distributions for Wi(xi) and Zi(wj ,x), and
hence Ti(wj ,x), that obey the identification Assumptions 3–6.
Subjects in partnerships are endowed with individual characteristics L that may be correlated. In
the randomized trial simulation, the vaccine is randomized in accordance with a specified distri-
bution – Bernoulli, block, or cluster randomization – without regard to these traits. Under each
randomization design, the marginal treatment probability Pr(Xi = xi) is 1/2. For Bernoulli ran-
domization, Pr(X = x) = 1/4, for block randomization, Pr(X = x) = 1{∑i xi = 1}/2, and for
cluster randomization, Pr(X = (1, 1)) = 1/2 and Pr(X = (0, 0)) = 1/2. In the observational study
simulation, the traits L = l together determine the joint distribution of vaccine in the partnership
as
Pr(Xi = 1|Li = li) = 1
1 + e−li
where (
Li
Lj
)
∼ Normal
((
0
0
)
, v
(
1 ρ
ρ 1
))
with v > 0.
Figure 3 illustrates controlled infection outcomes E[Yi(t;wj ,x)] over time for different choices of
wj and x, under the time-invariant hazard models. Contrasts of these potential infection outcomes
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give controlled contagion, susceptibility and infectiousness effects, shown in the lower-right corner
of Figure 3.
Tables 1 and 2 show estimates of the natural contagion, susceptibility and infectiousness effects from
simulated data, and compare these values to alternative estimands proposed by other authors, in-
cluding the direct effect DE(t), the indirect effect IDE(t), the secondary attack rate infectiousness
effect VEnetI (t), and CVE
c
I(t) bounds introduced by [17]. All natural or marginal estimands are
evaluated at time t = 2 years under each design and under both time-invariant and time-varying
baseline hazards with a sample size N = 100,000 partnerships. Estimands that are not identified
under a given design are not evaluated. Table 1 shows a simulation example where the estimated
direct effect DE(t) is positive (0.06 and 0.08) under block randomization when the disease is con-
tagious, even though the true susceptibility effect is negative, or beneficial [see, e.g. 13, 33]. Table
2 shows another simulation setting where DE(t) achieves the same sign as the susceptibility effect.
But in the setting without contagion, the disease is not contagious and infection outcomes are real-
ized independently. Therefore, all “indirect” and “infectiousness” effects should be null. However,
VEnetI (t) is negative (-0.01 and -0.02 in both Table 1 and 2), conflicting with the fact that the dis-
ease is not transmissible (as proved in Theorem 3). The identification interval CVEcI(t) has nonzero
width, but covers zero. Figure 4 compares estimates of different types of natural susceptibility and
infectiousness effects over time, when both effects are beneficial (negative). In the bottom-right
panel of Figure 4, we show that DE(t) under block randomization can suffer from directional bias.
7 Discussion
We have described a nonparametric framework for identifying causal intervention effects under con-
tagion in general two-person partnerships. The estimands and identification results generalize those
given in prior work [17, 36, 55, 56], and establish that point identification of clinically meaningful
causal estimands under contagion is possible even when relationships are symmetric and either
individual can be treated. We have made no assumptions about the functional form of infection
risks (beyond the independencies and exclusion restrictions implied by Assumptions 1–6), how the
risk of infection to a susceptible individual changes when their partner becomes infected, or how
the vaccine changes susceptibility or infectiousness over time. The framework respects the logic of
infectious disease transmission: if the outcome is not transmissible, the contagion and infectiousness
effects are zero.
By studying the role of a partner’s infection time in the identification of controlled causal effects,
we can identify causal estimands that are both more fundamental and more directly linked to the
biological effect of a vaccine on infection risk than simple contrasts of infection rates. Our results
also show that while some crude contrasts can recover causal effects in restricted settings (e.g. the
infectious effect VEI(t) in the asymmetric partnership setting) or under a particular randomization
design (e.g. the direct effect DE(t) under independent Bernoulli randomization), they may not
deliver useful summaries of vaccine effects in more general situations. Finally, the framework
developed in this paper may be useful in settings beyond infectious disease epidemiology, where
symmetric mediated effects are of interest [e.g. 49, 51].
One important limitation of our identification approach is that the controlled estimands and cross-
world natural estimands require observation of infection times, and not just binary infection in-
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Figure 3: Illustration of average controlled potential infection outcomes under different values of
the infection time wj and joint treatment x, under time-invariant baseline hazards α(t) = 0.2 and
γ(t − wj) = 10 and coefficients eβ0 = eβ1 = 0.2 and eσ = 0.5. Contrasts of potential outcomes in
(a), (b) and (c) show the controlled contagion effect, the infectiousness effect, and the susceptibility
effect evaluated at different times, shown together in (d).
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Figure 4: Comparison of different natural infectiousness and susceptibility effects. Figure a) com-
pares different natural infectiousness effects – natural infectiousness effect IE(t, xi = 0), crude
infectiousness effect VEnetI (t), the infectiousness defined in mediation analysis VEI(t) and bounds
identified by principal stratification – when both true susceptibility effect and true infectiousness
effect are beneficial (eβ = 0.2, eσ = 0.5). Similarly, Figure b) shows the same comparison of
multiple natural infectiousness effects as in Figure a) when the true infectiousness effect is much
stronger than the true susceptibility effect (eβ = 0.4, eσ = 0.01). Figure c) shows the comparison of
different types of natural susceptibility effect – the natural susceptibility effect SE(t, 0), the crude
susceptibility effect DE(t) under Bernoulli, Complete, and Cluster randomization – when both true
susceptibility effect and true infectiousness effect are beneficial (eβ = 0.2, eσ = 0.5) as in Figure a).
Likewise, Figure d) shows the same comparison of multiple natural susceptibility effects when the
true infectiousness effect is much stronger than the true susceptibility effect (eβ = 0.4, eσ = 0.01).
All four graphs are under constant baseline hazards α(t) = 0.2 and γ(t) = 10.
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dicators at a follow-up time t. In real-world vaccine trials, it may be unreasonable to require
investigators to measure infection times Ti with precision, as is required by Lemma 1 and Theorem
1. Instead, cross-sectional infection assessment, follow-up surveys, or tests for biomarkers of prior
infection are commonly used as the primary outcome. Corollary 1 shows exactly how controlled
effects that rely on infection times relate to natural effects that do not. Attempts to disentangle
individual effects from the mediating effects of treatment to partners using only binary infection
outcomes may fail to recover useful controlled or marginal effects [see, e.g. VEnetI , analyzed by 17].
Finally, while the symmetric partnership setting is useful for conceptualizing, defining, and identify-
ing causal estimands, real-world vaccine trials usually happen in clusters of varying sizes. Adapting
the setting outlined here to larger clusters results in rapid expansion of the number of potential out-
comes, corresponding to every possible ordering of infections, necessitating simplifying structural
assumptions to reduce the dimensionality of the problem. One promising avenue for dramatically
reducing the number of potential outcomes without imposing a parametric structure was proposed
by Kenah [28, 29]. The idea is that contagion works by competing risks, where hazards of infection
from different sources are additive. This approach imposes no additional structure on the distribu-
tion of the initial time to infection, but assumes that new infected cluster members always add a
competing risk of infection to the already existing risks of infection for susceptibles.
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A Proofs
Proof of Lemma 1. Let fi(w|xi, li) be the density of Wi(xi) when Li = li and let Fi(w|xi, li) be
the corresponding cumulative distribution function. By Assumption 4, 0 < Fi(w|xi, li) < 1 for all
w > 0, xi, and li, so we can write
fi(w|xi, li)
1− Fi(w|xi, li) = −
d
dw
log(1− Fi(w|xi, li)).
Then rearranging, we have
Fi(w|xi, li) = 1− exp
[
−
∫ w
0
fi(u|xi, li)
1− Fi(u|xi, li))du
]
= 1− exp
[
−
∫ w
0
fi(u|xi, li)(1− Fj(u|xj , lj))
(1− Fi(u|xi, li))(1− Fj(u|xj , lj))du
]
= 1− exp
[
−
∫ w
0
p(Wi(xi) = u,Wj(xj) > u|X = (xi, xj),L = (li, lj))
Pr(Wi(xi) > u,Wj(xj) > u|X = (xi, xj),L = (li, lj))du
]
= 1− exp
[
−
∫ w
0
p(Ti = u, Tj > u|X = (xi, xj),L = (li, lj))
Pr(Ti > u, Tj > u|X = (xi, xj),L = (li, lj))du
]
,
where xj is any fixed value of Xj and lj is any fixed value of Lj .
Lemma 2. Under Assumptions 1–3, Yi(t;wj ,x) |= Wj(xj) | L and Yi(t;wj ,x) |= X|L.
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Proof of Lemma 2. Fix a value wj > 0 and let x = (xi, xj). If Wi(xi) < wj , then Ti(wj ,x) = Wi(xi)
and by Assumption 1, Wi(xi) |= Wj(xj) | L, so Ti(wj ,x) |= Wj(xj) | L. If Wi(xi) > wj then
Ti(wj ,x) = wj + Zi(wj ,x) and by Assumption 2 Zi(wj ,x) |= Wj | L, so Ti(wj ,x) |= Wj(xj) | L.
Therefore, since Yi(t;wj ,x) = 1{Ti(wj ,x) < t}, it follows that Yi(t;wj ,x) |= Wj(xj) | L.
By the same reasoning, if Wi(xi) < wj , then Ti(wj ,x) = Wi(xi) and by Assumption 3, Wi(xi) |= X |
L. If Wi(xi) > wj then Ti(wj ,x) = wj + Zi(wj ,x) and by Assumption 3, Zi(wj ,x) |= X | L.
Therefore, since Yi(t;wj ,x) = 1{Ti(wj ,x) < t}, it follows that Yi(t;wj ,x) |= X | L.
Lemma 3. Under Assumptions 1-4, E[Yi(t, wj ,x)] = E[Yi(t)|Wj = wj ,X = x].
Proof of Lemma 3. Fix a value wj > 0 and x = (xi, xj). If Wi(xi) ≥ wj then
E[Yi(t, wj ,x)] = Pr(Ti(wj ,x) < t) by the definition of Yi(t, wj ,x)
= Pr(wj + Zi(wj ,x) < t) by the definition of Ti(wj ,x) and Wi(xi) ≥ wj
= Pr(Zi(wj ,x) < t− wj)
= Pr(Zi(wj ,x) < t− wj |Wj = wj) by Assumption 2
= Pr(Zi(wj ,x) < t− wj |Wj = wj ,X = x) by Assumption 3
= Pr(Zi < t− wj |Wj = wj ,X = x) by Assumption 4
= Pr(Zi < t−Wj |Wj = wj ,X = x)
= Pr(Zi +Wj < t|Wj = wj ,X = x)
= Pr(Ti < t|Wj = wj ,X = x) by the definition of Ti
= E[Yi(t)|Wj = wj ,X = x] by the definition of Yi(t)
If Wi(xi) < wj then
E[Yi(t, wj ,x)] = Pr(Ti(wj ,x) < t) by the definition of Yi(t, wj ,x)
= Pr(Wi(xi) < t) by the definition of Ti(wj ,x) and Wi(xi) < wj
= Pr(Wi(xi) < t|Xi = xi, Xj = xj) by Assumption 3
= Pr(Wi(xi) < t|Wj = wj , Xi = xi, Xj = xj) by Assumption 1
= Pr(Wi < t|Wj = wj ,X = x) by Assumption 4
= Pr(Ti < t|Wj = wj ,X = x) by the definition of Ti
= E[Yi(t)|Wj = wj ,X = x] by the definition of Yi(t)
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Proof of Theorem 1. The average potential infection outcome when L = l is given by
E[Yi(t;wj ,x)|L = l] = E[Yi(t;wj ,x)|Wj = wj ,X = x,L = l]
by Lemma 2
= E[Yi(t;wj ,x)|Wi ≤ wj ,Wj = wj ,X = x,L = l] Pr(Wi ≤ wj |Wj = wj ,X = x,L = l])
+ E[Yi(t;wj ,x)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Wj = wj ,X = x,L = l])
= Pr(Ti(wj ,x) < t|Wi ≤ wj ,Wj = wj ,X = x,L = l) Pr(Wi ≤ wj |Wj = wj ,X = x,L = l])
+ E[Yi(t;wj ,x)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Wj = wj ,X = x,L = l])
by the definition of Yi(t;wj ,x)
= Pr(Wi(xi) < t|Wi ≤ wj ,Wj = wj ,X = x,L = l) Pr(Wi ≤ wj |Wj = wj ,X = x,L = l])
+ E[Yi(t;wj ,x)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Wj = wj ,X = x,L = l])
by the definition of Ti(wj ,x)
= Pr(Wi(xi) < t|Wi ≤ wj , Xi = xi,L = l) Pr(Wi ≤ wj |Xi = xi,L = l])
+ E[Yi(t;wj ,x)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Xi = xi,L = l])
by Assumption 1
= Pr(Wi < t|Wi ≤ wj , Xi = xi,L = l) Pr(Wi ≤ wj |Xi = xi,L = l])
+ E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Xi = xi,L = l])
by Assumption 4 and Lemma 3
= Pr(Wi < t,Wj ≤ wj |Xi = xi,L = l)
+ E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Xi = xi,L = l])
When t ≥ wj , then
E[Yi(t;wj ,x)|L = l] = Pr(Wi < t,Wj ≤ wj |Xi = xi,L = l)
+ E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Xi = xi,L = l])
= Pr(Wi ≤ wj |Xi = xi,L = l])
+ E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Xi = xi,L = l])
= Fi(wj |xi, li) + (1− Fi(wj |xi, li))E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l].
Likewise, when t < wj , then
E[Yi(t;wj ,x)|L = l] = Pr(Wi < t,Wj ≤ wj |Xi = xi,L = l)
+ E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Xi = xi,L = l])
= Pr(Wi < t|Xi = xi,Li = li])
+ E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l] Pr(Wi > wj |Xi = xi,Li = li])
= Pr(Wi ≤ t|Xi = xi,Li = li])
since E[Yi(t)|Wi > wj ,Wj = wj ,X = x,L = l] = 0 when t < wj
= Fi(wj |xi, li).
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Proof of Corollary 1.
E[Yi(t;Wj(xj),x)|L = l] = E
[
E[Yi(t;Wj(xj),x)|L = l]
]
=
∫ ∞
0
E[Yi(t;u,x)|Wj = u,X = x,L = l]dFj(u|xj , li) by Assumption 1
=
∫ ∞
0
E[Yi(t)|Wj = u,X = x,L = l]dFj(u|xj , li) by Lemma 3 and Assumption 4
= E[Yi(t)|X = x,L = l].
Likewise, when x = (xi, xj) and x
′
j 6= xj ,
E[Yi(t;Wj(x′j),x|L = l] = E
[
E[Yi(t;Wj(xj),x|L = l]
]
=
∫ ∞
0
E[Yi(t;u,x)|Wj = u,X = x,L = l]dFj(u|x′j , li) by Assumption 1
=
∫ ∞
0
E[Yi(t)|Wj = u,X = x,L = l]dFj(u|x′j , li) by Lemma 3 and Assumption 4
Lemma 4. When SE(t, wj , xj) = 0, then Fj(t|xj) = Fj(t|1 − xj) and E[Yi(t)|Xi = 1, Xj = xj ] =
E[Yi(t)|Xi = 0, Xj = xj ], for all xj ∈ {0, 1} and t ≥ 0.
When SE(t, wj , xj) = IE(t, wj , xi) = 0, then E[Yi(t)|Xi = 0, Xj = 1] = E[Yi(t)|Xi = 0, Xj = 0].
When SE(t, wj , xj) = 0 and IE(t, wj , xi) < 0, then E[Yi(t)|Xi = 0, Xj = 1] < E[Yi(t)|Xi = 0, Xj =
0].
Proof of Lemma 4. First we prove Fj(t|xj) = Fj(t|1−xj), for all xj ∈ {0, 1} when SE(t, wj , xj) = 0.
Fj(t|xj) = Pr(Wj(xj) < t) = Pr(Tj(wi =∞, xi, xj) < t) by the definition of Tj(wi, xj , xi)
= E[Yj(t;wi =∞, xj , xi)] by the definition of Yj(u;wi, xj , xi)
= E[Yi(t;wi =∞, x′j , xi)] since SE(t, wj , xj) = 0
= Pr(Wj(x
′
j) < t) = Fj(t|x′j).
(6)
Second, we prove E[Yi(t)|Xi = 1, Xj = xj ] = E[Yi(t)|Xi = 0, Xj = xj ] for all xj ∈ {0, 1}, if
SE(t, wj , xj) = 0.
E[Yi(t)|Xi = 1, Xj = xj ] =
∫ ∞
0
E[Yi(t)|Wj = u,Xi = 1, Xj = xj ]dFj(u|xj) by Assumption 1
=
∫ ∞
0
E[Yi(t;u, xi = 1, xj)]dFj(u|xj) by Lemma 3
=
∫ ∞
0
E[Yi(t;u, xi = 0, xj)]dFj(u|xj) since SE(t, wj , xj) = 0
= E[Yi(t)|Xi = 0, Xj = xj ].
(7)
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Third, by (6), we prove E[Yi(t)|Xi = 0, Xj = 1] = E[Yi(t)|Xi = 0, Xj = 0], if SE(t, wj , xj) =
IE(t, wj , xi) = 0.
E[Yi(t)|Xi = 0, Xj = 1] =
∫ t
0
E[Yi(t)|Wj = u,Xi = 0, Xj = 1]dFj(u|1) by Assumption 1
=
∫ ∞
0
E[Yi(t;u, xi = 0, xj = 1)]dFj(u|1) by Lemma 3
=
∫ ∞
0
E[Yi(t;u, xi = 0, xj = 0)]dFj(u|1) since IE(t, wj , xi) = 0
=
∫ ∞
0
E[Yi(t;u, xi = 0, xj = 0)]dFj(u|0) by (6)
=
∫ ∞
0
E[Yi(t)|Wj = u,Xi = 0, xj = 0)]dFj(u|0) by Lemma 3
= E[Yi(t)|Xi = 0, Xj = 0].
(8)
Fourth, by (6), we prove E[Yi(t)|Xi = 0, Xj = 1] < E[Yi(t)|Xi = 0, Xj = 0], if SE(t, wj , xj) = 0 and
IE(t, wj , xi) < 0.
E[Yi(t)|Xi = 0, Xj = 1] =
∫ t
0
E[Yi(t)|Wj = u,Xi = 0, Xj = 1]dFj(u|1) by Assumption 1
=
∫ ∞
0
E[Yi(t;u, xi = 0, xj = 1)]dFj(u|1) by Lemma 3
<
∫ ∞
0
E[Yi(t;u, xi = 0, xj = 0)]dFj(u|1) since IE(t, wj , xi) < 0
=
∫ ∞
0
E[Yi(t;u, xi = 0, xj = 0)]dFj(u|0) by (6)
=
∫ ∞
0
E[Yi(t)|Wj = u,Xi = 0, xj = 0)]dFj(u|0) by Lemma 3
= E[Yi(t)|Xi = 0, Xj = 0].
(9)
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Proof of Theorem 2. Given the conclusions from (7) and (9), we have
DE(t) = E[Yi(t)|Xi = 1]− E[Yi(t)|Xi = 0]
= E[Yi(t)|Xi = 1, Xj = 1] Pr(Xj = 1|Xi = 1) + E[Yi(t)|Xi = 1, Xj = 0] Pr(Xj = 0|Xi = 1)
− E[Yi(t)|Xi = 0, Xj = 1] Pr(Xj = 1|Xi = 0)− E[Yi(t)|Xi = 0, Xj = 0] Pr(Xj = 0|Xi = 0)
= E[Yi(t)|Xi = 0, Xj = 1] Pr(Xj = 1|Xi = 1) + E[Yi(t)|Xi = 0, Xj = 0] Pr(Xj = 0|Xi = 1)
− E[Yi(t)|Xi = 0, Xj = 1] Pr(Xj = 1|Xi = 0)− E[Yi(t)|Xi = 0, Xj = 0] Pr(Xj = 0|Xi = 0)
by (7) in Lemma 4
= E[Yi(t)|Xi = 0, Xj = 1]
[
Pr(Xj = 1|Xi = 1)− Pr(Xj = 1|Xi = 0)
]
+ E[Yi(t)|Xi = 0, Xj = 0]
[
Pr(Xj = 0|Xi = 1)− Pr(Xj = 0|Xi = 0)
]
= E[Yi(t)|Xi = 0, Xj = 1]
[
Pr(Xj = 1|Xi = 1)− Pr(Xj = 1|Xi = 0)
]
+ E[Yi(t)|Xi = 0, Xj = 0]
{
[1− Pr(Xj = 1|Xi = 1)]− [1− Pr(Xj = 1|Xi = 0)]
}
=
{
E[Yi(t)|Xi = 0, Xj = 1]− E[Yi(t)|Xi = 0, Xj = 0]
}
·
[
Pr(Xj = 1|Xi = 1)− Pr(Xj = 1|Xi = 0)
]
(10)
Note by (9) in Lemma 4, we have the first term at the last line of (10) being negative. The sign
of DE(t) then depends only on the treatment assignment mechanism, which leads to the following
conclusions for DE(t).
1. If the treatment assignment is positively correlated (Pr(Xi = c,Xj = c) > Pr(Xi = c) Pr(Xj = c)
for c ∈ 0, 1), we have:
Pr(Xj = 1|Xi = 1)− Pr(Xj = 1|Xi = 0)
=
Pr(Xj = 1, Xi = 1)
Pr(Xi = 1)
− Pr(Xj = 1, Xi = 0)
Pr(Xi = 0)
=
Pr(Xj = 1, Xi = 1) Pr(Xi = 0)− Pr(Xj = 1, Xi = 0) Pr(Xi = 1)
Pr(Xi = 1) Pr(Xi = 0)
=
Pr(Xj = 1, Xi = 1)[1− Pr(Xi = 1)]− Pr(Xj = 1, Xi = 0) Pr(Xi = 1)
Pr(Xi = 1) Pr(Xi = 0)
=
Pr(Xj = 1, Xi = 1)− Pr(Xj = 1, Xi = 1) Pr(Xi = 1)− Pr(Xj = 1, Xi = 0) Pr(Xi = 1)
Pr(Xi = 1) Pr(Xi = 0)
=
Pr(Xj = 1, Xi = 1)− Pr(Xj = 1 Pr(Xi = 1)
Pr(Xi = 1) Pr(Xi = 0)
≥ 0
(11)
Thus, DE(t) < 0.
2. If the treatment assignment is independent (Pr(Xi = c,Xj = c) = Pr(Xi = c) Pr(Xj = c) for
c ∈ 0, 1), then by similar arguments of (11), we have Pr(Xj = 1|Xi = 1)− Pr(Xj = 1|Xi = 0) = 0.
Thus, DE(t) = 0.
3. If the treatment assignment is negatively correlated (Pr(Xi = c,Xj = c) < Pr(Xi = c) Pr(Xj =
c) for c ∈ 0, 1), then by similar arguments of (11), we have Pr(Xj = 1|Xi = 1) − Pr(Xj = 1|Xi =
0) < 0. Thus, DE(t) > 0.
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When IE(t, wj , xi) = 0, following (8) and (10) in Lemma 4, we have E[Yi(t)|Xi = 0, Xj = 1] =
E[Yi(t)|Xi = 0, Xj = 0] and thus DE(t) = 0.
Similar arguments apply for VEAR(t).
Proof of Theorem 3. We evaluate the sign of VEnetI (t) by analyzing SAR00(t)− SAR10(t).
VEnetI (t) = 1−
SAR10(t)
SAR00(t)
=
SAR00(t)− SAR10(t)
SAR00(t)
First, we analyze the sign of VEnetI (t) under a null true infectiousness effect, when the infection
outcome is positively contagions and vaccine has a favorable effect prior first infection through
h0(u|1) = εh0(u|0), for ε ∈ [0, 1).
SAR10(t)− SAR00(t)
= E[Yi(t)|Tj < t, Ti > Tj , Xi = 0, Xj = 1]− E[Yi(t)|Tj < t, Ti > Tj , Xi = 0, Xj = 0]
=
∫ t
0 E[Yi(t)|Wj = u,Wi > u,X = (0, 1)](1− Fi(u|0))dFj(u|1)
Pr(Wj < t,Wi > Wj |X = (0, 1))
−
∫ t
0 E[Yi(t)|Wj = u,Wi > u,X = (0, 0)](1− Fi(u|0))dFj(u|0)
Pr(Wj < t,Wi > Wj |X = (0, 0))
by applying the law of total probability
=
∫ t
0
E[Yi(t)|Wj = u,Wi > u,X = (0, 1)] (1− Fi(u|0))dFj(u|1)∫ t
0 (1− Fi(v|0))dFj(v|1)
−
∫ t
0
E[Yi(t)|Wj = u,Wi > u,X = (0, 0)] (1− Fi(u|0))dFj(u|0)∫ t
0 (1− Fi(v|0))dFj(v|0)
=
∫ t
0
E[Yi(t)|Wj = u,Wi > u,X = (0, 0)]
[ (1− Fi(u|0))dFj(u|1)∫ t
0 (1− Fi(v|0))dFj(v|1)
− (1− Fi(u|0))dFj(u|0)∫ t
0 (1− Fi(v|0))dFj(v|0)
]
.
By IE(t, wj , 0) = 0 and Lemma 3
(12)
To ease the notation in Equation (12), we denote E[Yi(t)|Wj = u,Wi > u,X = (0, 0)] = k(u).
Denote g(u|1) = (1−Fi(u|0))dFj(u|1)∫ t
0 (1−Fi(v|0))dFj(v|1)
and g(u|0) = (1−Fi(u|0))dFj(u|0)∫ t
0 (1−Fi(v|0))dFj(v|0)
, and G(u|1) = ∫ u0 g(s|1)ds and
G(u|0) = ∫ u0 g(s|0)ds. Then by integration by parts, (12) can be re-written as follows:
SAR10(t)− SAR00(t) =
∫ t
0
k(u)[g(u|1)− g(u|0)]du
= k(u)[G(u|1)−G(u|0)]
∣∣∣t
0
−
∫ t
0
(G(u|1)−G(u|0))dk(u).
By their definitions, we have G(0|1)−G(0|0) = 0 and G(t|1)−G(t|0) = 0, and thus k(u)[G(u|1)−
G(u|0)]
∣∣∣t
0
= 0. In other words, the sign of SAR10(t) − SAR00(t) only depends on the sign of
G(u|1) − G(u|0) and dk(u) for all u > 0. First, we can show that dk(u) < 0 for 0 ≤ u < t. For
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0 ≤ u < u′ < t, we have
k(u) =
E[Yi(t)|Wj = u,X = (0, 0)]− Fi(u|0)
1− Fi(u|0) by Theorem 1
>
E[Yi(t)|Wj = u′,X = (0, 0)]− Fi(u|0)
1− Fi(u|0) by CE(t, u, u
′, (0, 0)) > 0
=
E[Yi(t)|Wj = u′,X = (0, 0)]− Fi(u′|0) + Fi(u′|0)− Fi(u|0)
1− Fi(u|0)
=
k(u′)(1− Fi(u′|0)) + Fi(u′|0)− Fi(u|0)
1− Fi(u|0) by Theorem 1
≥ k(u
′)(1− Fi(u′|0)) + (Fi(u′|0)− Fi(u|0))k(u′)
1− Fi(u|0) by k(u
′) ≤ 1
=
k(u′)(1− Fi(u|0))
1− Fi(u|0) = k(u
′).
(13)
Next, we analyze the property of G(u|1)−G(u|0) for ∀u > 0. Denote H0(u) =
∫ u
0 h0(s|0)ds. Given
h0(u|1) = εh0(u|0) with ε ∈ [0, 1), we can write out G(u|0) and G(u|1) in terms of h0(u|0) as
follows.
G(s|1) =
∫ s
0 (1− Fi(u|0))dFj(u|1)∫ t
0 (1− Fi(v|0))dFj(v|1)
=
∫ s
0 ε · h0(u|0)e−ε·H0(u)e−H0(u)du∫ t
0 ε · h0(v|0)e−ε·H0(v)e−H0(v)dv
=
∫ s
0 ε · h0(u|0)e−(ε+1)·H0(u)du∫ t
0 ε · h0(v|0)e−(ε+1)·H0(v)dv
=
1− e−(ε+1)H0(s)
1− e−(ε+1)H0(t)
G(s|0) =
∫ s
0 (1− Fi(u|0))dFj(u|1)∫ t
0 (1− Fi(v|0))dFj(v|1)
=
1− e−2H0(s)
1− e−2H0(t)
(14)
From (14), we observe that G(s|1) and G(s|0) only differ by the terms in front of H0. Treat G(s|1)
and G(s|0) as functions of ε, and we can re-express them as G(ε) = 1−e−(ε+1)H0(s)
1−e−(ε+1)H0(t) and G(1) =
1−e−2H0(s)
1−e−2H0(t) , given ε < 1. Then, if G(ε) is a decreasing function of ε, we have G(u|1)−G(u|0) ≤ 0.
∂
∂ε
G(ε) =
H0(u)e
−(ε+1)H0(u)[1− e−(ε+1)H0(t)]−H0(t)e−(ε+1)H0(t)[1− e−(ε+1)H0(u)]
[1− e−(ε+1)H0(t)]2 (15)
Divide the numerator of (15) by a positive constant H0(t)H0(u)e
−(ε+1)[H0(u)+H0(t)]. We then have
if e
(ε+1)H0(u)−1
H0(u)
≤ e(ε+1)H0(t)−1H0(t) for u < t, then G(u|1)−G(u|0) ≤ 0. Treat e
(ε+1)H0(t)−1
H0(t)
as a function
of u, given 0 ≤ u < t. We have,
∂
∂u
e(ε+1)H0(u) − 1
H0(u)
=
(ε+ 1)H0(u)e
(ε+1)H0(u) − e(ε+1)H0(u) + 1
[H0(u)]2
=
(ε+ 1)H0(u)− 1 + e−(ε+1)H0(u)
[H0(u)]2e(ε+1)H0(u)
by e−(ε+1)H0(u) ≥ 1− (ε+ 1)H0(u)
≥ 0.
(16)
Combining (15) and (16), we have G(u|1)−G(u|0) ≤ 0.
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In summary, we can see that
SAR10(t)− SAR00(t) = k(u)[G(u|1)−G(u|0)]
∣∣∣t
0
−
∫ t
0
(G(u|1)−G(u|0))dk(u) < 0
Thus, VEnetI (t) = 1− SAR10(t)SAR00(t) =
SAR00(t)−SAR10(t)
SAR00(t)
> 0.
Second, we analyze the sign of VEnetI (t) under a null true infectiousness effect, when the true
susceptibility effect is also null.
SAR10(t)− SAR00(t)
=
∫ t
0
E[Yi(t)|Wj = u,Wi > u,X = (0, 0)]
[ (1− Fi(u|0))dFj(u|1)∫ t
0 (1− Fi(v|0))dFj(v|1)
− (1− Fi(u|0))dFj(u|0)∫ t
0 (1− Fi(v|0))dFj(v|0)
]
by (12)
=
∫ t
0
E[Yi(t)|Wj = u,Wi > u,X = (0, 0)]
[ (1− Fi(u|0))dFj(u|0)∫ t
0 (1− Fi(v|0))dFj(v|0)
− (1− Fi(u|0))dFj(u|0)∫ t
0 (1− Fi(v|0))dFj(v|0)
]
by SE(t, wj , xj) = 0 and (6)
= 0.
Thus, VEnetI (t) = 1− SAR10(t)SAR00(t) =
SAR00(t)−SAR10(t)
SAR00(t)
= 0.
Third, we analyze the sign of VEnetI (t) in the case of no contagion, when the true susceptibility
effect is beneficial. First, CE(t, wj , w
′
j ,0) = 0 for all 0 < wj < w
′
j implies IE(t, wj , 0) = 0.
IE(t, wj , xi) = E[Yi(t;wj , xi, xj = 1)− Yi(t;wj , xi, xj = 0)]
= E[1{Wi(xi) < t} − 1{Wi(t;xi) < t}] = 0
Following the same proof for the first case except replacing the second line of (13) by an equal sign,
we know VEnetI (t) > 0.
Proof of Theorem 4. Given hi0(t|0) = 0, we have Fi(s|0) = 1− e−
∫ s
0 h
i
0(u|0)du = 0 for Wi(0).
E[Yi(t;Yj(x′j), (0, xj))|hi0(t|0) = 0] = E[Yi(t;Yj(x′j), (0, xj))|Wi(0) =∞]
by Fi(s|xi) = 0 for ∀s > 0
= E[Yi(t; 1{Wj(x′j) < t}, (0, xj))|Wi(xi) =∞]
given Yi(x
′
j) = {Tj(x′j) < t} and Tj(x′j) = Wj(0) when Wi(0) =∞
= E[Yi(t;Wj(x′j), (0, xj))|Wi(0) =∞]
= E[Yi(t;Wj(x′j), (0, xj))|hi0(s|0) = 0]
(17)
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Thus, by the definition of VEI(t) and IE(t, xi), we have:
VEI(t) = E[Yi(t;Yj(1), (0, 1))− Yi(t;Yj(1), (0, 0))|hi0(s|0) = 0]
= E[Yi(t;Wj(1), (0, 1))− Yi(t;Wj(1), (0, 0))|hi0(s|0) = 0] = IE(t, 0|hi0(s|0) = 0)
Thus, VEI is equivalent to the natural infectiousness effect under the asymmetric partnership.
Proof of Theorem 5. Given hi0(t|0) = 0, we have Fi(t|0) = 1− e−
∫ t
0 h
i
0(u|0)du = 0.
VEC(t) = E[Yi(t;Yj(1), (0, 0))]− E[Yi(t;Yj(0), (0, 0))]
= E[Yi(t;Wj(1), (0, 0))]− E[Yi(t;Wj(0), (0, 0))]
by Equation (17)
=
∫ ∞
0
E[Yi(t;wj , (0, 0))]dFj(wj |1)−
∫ ∞
0
E[Yi(t;wj , (0, 0)]dFj(wj |0)
by Corollary 1
=
∫ ∞
0
{
Fi(wj |0) + (1− Fi(wj |0))E[Yi(t)|Wi > wj ,Wj = wj ,X = (0, 0)]
}
d(Fj(wj |1)− Fj(wj |0))
by Theorem 1
=
∫ ∞
0
E[Yi(t)|Wi > wj ,Wj = wj ,X = (0, 0)]d(Fj(wj |1)− Fj(wj |0))
by Fi(t|xi) = 0 for ∀t > 0
=
∫ t
0
E[Yi(t)|Wi > wj ,Wj = wj ,X = (0, 0)]d(Fj(wj |1)− Fj(wj |0))
since E[Yi(t)|Wi > wj ,Wj = wj ,X = (0, 0)] = 0 for wj > t
=
∫ t
0
k(wj)d(Fj(wj |1)− Fj(wj |0))
by the definition of k(u) in the proof of Theorem 3
= k(wj)[Fj(wj |1)− Fj(wj |0)]
∣∣∣t
0
−
∫ t
0
Fj(wj |1)− Fj(wj |0)dk(wj)
by integration by parts
By the definition of k(u) and Fj(u|xj), we know k(t) = 0 and Fj(0|1) − Fj(0|0) = 0, and thus
k(wj)[Fj(wj |1) − Fj(wj |0)]
∣∣∣t
0
= 0. If SE(t, wj , x) > 0, we have Fj(wj |1) − Fj(wj |0) > 0. If
CE(t, u, u′, (0, 0)) > 0 for 0 ≤ u < u′ < t, dk(u) < 0 as shown in the the proof of Theorem 3.
Thus, we have the following conclusions.
When SE(t, wj , x) > 0, VEC(t) has the opposite sign as CE(t, u
′, u, (0, 0)).
If SE(t, wj , x) = 0 and CE(t, u, u
′, (0, 0)) > 0, we have VEC(t) = 0.
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